Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle

Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).